TY  - JOUR
T1  - Ege Üniversitesi Hastanesinde glioblastomaların epidemiyolojik ve sağ kalım özellikleri
TT  - Epidemiological and survival features of glioblastomas in Ege University Hospital
AU  - Kamer, Serra
AU  - Öztürk, Meltem
AU  - Ertan, Yeşim
AU  - Özgiray, Erkin
AU  - Yurtseven, Taşkın
AU  - Şanlı, Ulus Ali
AU  - Haydaroğlu, Ayfer
PY  - 2019
DA  - December
DO  - 10.19161/etd.668263
JF  - Ege Tıp Dergisi
JO  - EJM
PB  - Ege University
WT  - DergiPark
SN  - 1016-9113
SP  - 19
EP  - 25
LA  - tr
AB  - Amaç: Ege Üniversitesi Hastanesi (EÜH) veri tabanındaki 1327 Glioblastoma (GBM) olgusununepidemiyolojik ve genel sağ kalım (GSK) özelliklerini istatistiksel açıdan değerlendirmektir.Gereç Yöntem: EÜ Kanserle Savaş Uygulama ve Araştırma Merkezi (EÜKAM) tarafından 1992-2017arasında kanser veri tabanında toplanan 117139 kanser verisi içindeki 1327 GBM olgusudeğerlendirilmiştir.Bulgular: 1327 GBM hastası analiz edilmiştir. Tanı anı ortalama yaş 55,6 yıl bulunmuştur.Erkek/kadın oranı 1,52:1’dir. En sık tutulumun temporal lobta (%36,3) olduğu saptanmıştır. Tedavisiraporlanan 881 hastanın analizinde; olguların %30,2’sine yalnızca operasyon, %65,6’sına kombinetedaviler uygulanmıştır. Otuz beş hastada (%4,0) yalnızca radyoterapi (RT) uygulanırken 558 hastada(%63,3) kombine tedavide RT eklenmiştir. Tüm GBM hastalarının ortalama sağ kalım süresi 12,15aydır. Bir, iki, üç ve beş yıllık GSK oranları sırasıyla %50,4, %22,02, %11 ve %5’tir. Ortalama sağkalım erkeklerde 11,6 ay, kadınlarda 13,3 ay olarak saptanmıştır. Cinsiyet ile sağ kalım süresiarasında anlamlı ilişki saptanmamıştır. Yaş gruplarına göre sağ kalım analizinde ileri yaş gruplarındasağ kalımın anlamlı olarak azaldığı saptanmıştır (p<0,001). Cerrahi, RT ve kemoterapi (KT) uygulananhastaların bir ve beş yıllık GSK oranının diğer tedavi şekillerine göre daha yüksek olduğu saptanmıştır(p<0,001). Ortalama sağ kalım RT alan grupta 14,0 ay, almayanlarda ise 9,4 ay olarak bulunmuştur(p<0,001).Sonuçlar: Çalışmamızda tanı yaşı, eşzamanlı ve adjuvan KT (Temozolomid) tedavisi sağ kalımıetkileyen prognostik faktörler olarak bulunmuştur. Cinsiyet ve tümör lokalizasyonu ile sağ kalımarasında anlamlı fark saptanmamıştır. Günümüzde maksimum cerrahi rezeksiyon ve ardındanadjuvan kemoradyoterapi, GBM yönetiminin temel standardı olup, ortalama 12 aylık GSKsağlamaktadır.
KW  - Beyin tümörleri
KW  - glioblastoma
KW  - radyoterapi
N2  - Aim: The aim of this study was to evaluate the epidemiological and overall survival rates(OS) of 1327cases of Glioblastoma (GBM) in Ege University Hospital (EÜH) database.Materials and Methods: 1327 GBM cases were evaluated in 117139 cancer data collected from thecancer database between 1992 and 2017 by the EU Cancer Control Application and Research Center.Results: 1327 GBM patients were analyzed. The mean age at diagnosis was 55.6 years. Themale/female ratio was 1.52:1. The most common involvement was found in temporal lobe (36.3%).Inanalysis of 881 patients whose treatment was reported. In 30.2% of the cases, only operation wasperformed and in 65.6% combined treatments were applied. RT was added in 558 patients (63.3%).The ortalama survival time of all GBM patients was 12.15 months. One, two, three and five-year OSrates were 50.4%, 22.02%, 11% and 5% respectively. Ortalama survival was 11.6 months for malesand 13.3 months for females No significant difference was found between sex and survival time.Survival analysis signify that survival decreased in older age groups (p<0.001).Patients who wastreated with surgery, RT and chemotherapy (CT) were found to have a higher 1 and 5-year OS ratecompared to other treatment modalities (p<0.001).Ortalama survival was 14.0 months in RT group and9.4 months in non-RT group (p<0.001).Conclusions: Age of diagnosis, concurrent and adjuvant chemotherapy (Temozolomide) were foundto be prognostic factors affecting survival. There was no significant difference between sex and tumorlocalization and survival. Maximum surgical resection followed by adjuvant chemoradiotherapy is thebasic standard of GBM management and provides an average of 12 months OS.
CR  - Jigisha P. Thakkar, Therese A. Dolecek, Craig Horbinski, Quinn T. Ostrom, Donita D. Lightner, Jill S. Barnholtz-Sloan, and John L. Villano1. Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiology, Biomarkers & Prevention 2014; DOI: 10.1158/1055-9965.EPI-14-0275.
CR  - M Ghosh, S Shubham, K Mandal, V Trivedi, R Chauhan, S Naseera. Survival and prognostic factors for glioblastoma multiforme: Retrospective single-institutional study. Indian Journal of Cancer; 2017;54/1:362—7.
CR  - Tomasz Tykocki, Mohamed Eltayeb. Ten-year survival in glioblastoma. A systematic review. Journal of Clinical Neuroscience 2018), https://doi.org/10.1016/j.jocn.2018.05.002.
CR  - Roger Stupp, M.D., Warren P. Mason, M.D., Martin J. van den Bent, M.D., Michael Weller, M.D., Barbara Fisher, M.D., Martin J.B. Taphoorn, M.D., Karl Belanger, M.D., Alba A. Brandes, M.D., Christine Marosi, M.D., Ulrich Bogdahn, M.D., Jurgen Curschmann, M.D., Robert C. Janzer, M.D., Samuel K. Ludwin, M.D.,Thierry Gorlia, M.Sc., Anouk Allgeier, Ph.D., Denis Lacombe, M.D., J. Gregory Cairncross, M.D., Elizabeth Eisenhauer, M.D., and Rene O. Mirimanoff, M.D. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. The new england journal of medicine, 2005; 352:987-96.
CR  - Supapan Witthayanuwat, Montien Pesee, Chunsri Supaadirek, Narudom Supakalin, Komsan Thamronganantasakul, Srichai Krusun. Survival Analysis of Glioblastoma Multiforme. Asian Pac J Cancer Prev, 2018;19(9):2613-7.
CR  - A Report of the Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: Development of a prognostic index; Journal of Neuro-Oncology, 1990;9: 47-55.
CR  - Johnson DR, Ma DJ, Buckner JC, Hammack JE. Conditional probability of longterm survival in glioblastoma. Cancer 2012;118:5608–13. https://doi.org/ 10.1002/cncr.27590.
CR  - Polley M-YC, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol 2011;29:4175–80. https://doi.org/10.1200/ JCO.2010.32.4343.
CR  - FG Davis, BJ McCarthy, S Freels, etal: The conditional probability of survival of patients with primary malignant brain tumors Cancer 85: 485– 91,1999 Crossref, Medline, Google Scholar
CR  - Anderson E, Grant R, Lewis SC, Whittle PIR. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br J Neurosurg 2008;22:339–49. https://doi.org/10.1080/02688690701885603.
CR  - Mitchell P, Ellison DW, Mendelow AD. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 2005;4:413–22. https://doi.org/10.1016/S1474-4422 (05) 70118-6.
CR  - Willems PWA, Taphoorn MJB, Burger H, Berkelbach van der Sprenkel JW, Tulleken CAF. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. J Neurosurg 2006;104:360–8. https://doi.org/10.3171/jns.2006.104.3.360.
CR  - Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. (PMC free article) (PubMed) (Google Scholar).
CR  - Abacıoğlu U, Çetin İ, Akgün Z, Şengöz M, Türk Onkoloji Dergisi, Cilt 19, Sayı 3, 2004;112-118.
UR  - https://doi.org/10.19161/etd.668263
L1  - https://dergipark.org.tr/en/download/article-file/911996
ER  -